ETFIQ
RankingsCompareHoldingsFlowsResearch
Ask ETFIQETF ModelsMy portfolioWeekly note
A
vs
B
Share on XDownload as PDFOpen liveCompare their flowsAsk about these two funds

ARKG vs XBI: which is really different?

ARKG and XBI hold 12% of their weight in the same names, and ARKG returned +62.1% over the year. ARK Genomic Revolution ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.

XBI costs 0.40 points a year less; their one-year returns differ by 17.1 points; XBI is 4.8 times larger.

ARKGXBI
Expense ratio0.75%0.35%
Net assets, as of Oct 8, 2026$2.0bn$9.9bn
Total return, 1 year+62.1%+45.0%
What it tracksGenomics and gene editingBiotech
Holdings in common12%
S&P 500, total return, 1 year+17.3%
Against the S&P 500, 1 yearahead by 44.8 ptsahead by 27.7 pts
Below its all-time high54.1%, high on Jan 20, 202111.1%, high on Feb 8, 2021

Holdings in common uses holdings dated Oct 8, 2026.

3.7%
ARKG in the S&P 500
12.7%
XBI in the S&P 500
+62.1%
ARKG total return, 1 year
+45.0%
XBI total return, 1 year
ARKG · 1 year to Oct 9, 202696% of its weight is outside the S&P 500
96% of its weight is outside the S&P 5004% of ARKG's weight is in S&P 500 companies and 96% is outside the index. Holdings as of Oct 8, 2026.4%96%inof its weight outside the S&P 500active share 99% · top ten 58% of the fund · 34 holdings as published by its issuer for Oct 8, 2026 · Nasdaq-100: 0% in96% of its weight is outside the S&P 5004% of ARKG's weight is in S&P 500 companies and 96% is outside the index. Holdings as of Oct 8, 2026.4%96%4% of its weight in S&P 500 companiesof its weight outside the S&P 500active share 99% · Nasdaq-100: 0% in

4% of ARKG's weight is in S&P 500 companies and 96% is outside the index. Holdings as of Oct 8, 2026.

XBI · 1 year to Oct 9, 202687% of its weight is outside the S&P 500
87% of its weight is outside the S&P 50013% of XBI's weight is in S&P 500 companies and 87% is outside the index. Holdings as of Oct 8, 2026.13%87%inof its weight outside the S&P 500active share 98% · top ten 17% of the fund · 165 holdings as published by its issuer for Oct 8, 2026 · Nasdaq-100: 9% in87% of its weight is outside the S&P 50013% of XBI's weight is in S&P 500 companies and 87% is outside the index. Holdings as of Oct 8, 2026.13%87%inof its weight outside the S&P 500active share 98% · Nasdaq-100: 9% in

13% of XBI's weight is in S&P 500 companies and 87% is outside the index. Holdings as of Oct 8, 2026.

ETFIQ Off-Index Score · ARKG scores higherHow much of it is not the index it is sold as an alternative to?
0.1, the lowest in this set92.3, the highest

A percentile among the 391 thematic ETFs with a holdings filing. All thematic ETFs ranked by it → How it is computed →

What they hold in common

By the books each fund has filed, ARKG and XBI hold 12% of their money in the same securities at the same weight. Above 50%, holding both is close to holding one of them twice. Holdings dated Oct 8, 2026.

half

12% in common

Positions both hold, largest shared weight first
Holding ARKG XBI
TWIST BIOSCIENCE CORP 8.55% 1.84%
NATERA INC 4.71% 1.79%
CRISPR THERAPEUTICS AG 5.25% 1.41%
IONIS PHARMACEUTICALS INC 1.84% 1.17%
VERACYTE INC 3.30% 1.04%
BEAM THERAPEUTICS INC 3.24% 0.87%
CAREDX INC 4.14% 0.84%
RECURSION PHARMACEUTICALS-A 2.84% 0.67%
INTELLIA THERAPEUTICS INC 1.85% 0.55%
NURIX THERAPEUTICS INC 2.23% 0.50%
KYMERA THERAPEUTICS INC 0.46% 1.20%
ABSCI CORP 4.62% 0.45%
Only in ARKG
10X GENOMICS INC-CLASS A 9.23%
TEMPUS AI INC-CL A 8.30%
ILLUMINA INC 4.78%
GUARDANT HEALTH INC 4.71%
PERSONALIS INC 4.01%
ELI LILLY & CO 3.73%
SCHRODINGER INC 2.89%
COMPASS PATHWAYS PLC 2.57%
Only in XBI
MODERNA INC 2.20%
ABBVIE INC 1.65%
UNITED THERAPEUTICS CORP 1.59%
AMGEN INC 1.58%
BIOGEN INC 1.57%
HALOZYME THERAPEUTICS INC 1.55%
IOVANCE BIOTHERAPEUTICS INC 1.54%
EXELIXIS INC 1.53%

12% of the two portfolios are the same securities at the same weight.

Performance, window by window

Total returnvs the S&P 500vs the Nasdaq-100
WindowARKGXBIARKGXBIARKGXBI
3 months+24.1%−3.3%+20.8 pts−6.7 pts+20.5 pts−7.0 pts
6 months+92.3%+18.9%+77.1 pts+3.8 pts+69.1 pts−4.3 pts
1 year+62.1%+45.0%+44.8 pts+27.7 pts+38.5 pts+21.4 pts
3 years+91.1%+114.6%+5.3 pts+28.8 pts−16.1 pts+7.3 pts
Since launch
ARKG Oct 2014 · XBI Feb 2006
+172.8%+890.7%−198.8 pts+92.2 pts−538.8 pts−1,164.7 pts

Source: ETFIQ. Open the live comparison on ETFIQ →

On the same fields

ARKG
ARK Genomic Revolution ETF · Holds 34 stocks in genomics and gene editing, 4% of its weight in S&P 500 companies
XBI
State Street(R) SPDR(R) S&P(R) Biotech ETF · Holds 165 stocks in biotech, 13% of its weight in S&P 500 companies
Issuer ARK State Street
Theme Genomics and gene editing Biotech
In the S&P 500 3.7% 12.7%
Active share vs the S&P 500 98.5% 98.4%
In the Nasdaq-100 0.0% 8.5%
Holdings 34 165
Top ten, share of the fund 58.3% 16.9%
Expense ratio 0.75% 0.35%
Fee for the differing part 0.76% 0.36%
Total return, 1 year +62.1% +45.0%
vs the S&P 500 +44.8 pts +27.7 pts
vs the Nasdaq-100 +38.5 pts +21.4 pts
Below its high −54.1% −11.1%
Net assets, as of Oct 8, 2026 $2.0bn $9.9bn

As of Oct 9, 2026. Source: ETFIQ.

ARKG in plain words

By weight, 4% of ARKG's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 58% of the fund across 34 positions, as published by its issuer for Oct 9, 2026. Over the year to Oct 9, 2026 the fund returned +62.1% with distributions reinvested against +17.3% for the S&P 500, so a holder was ahead by 44.8 pts. It sits 54.1% below its all-time high of Jan 20, 2021.

XBI in plain words

By weight, 13% of XBI's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 17% of the fund across 165 positions, as published by its issuer for Oct 8, 2026. Over the year to Oct 9, 2026 the fund returned +45.0% with distributions reinvested against +17.3% for the S&P 500, so a holder was ahead by 27.7 pts. It sits 11.1% below its all-time high of Feb 8, 2021.

Questions people ask

Do ARKG and XBI hold the same stocks?
By their latest filings, 12% of their books are the same securities at the same weight, which is mostly different names. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, ARKG or XBI?
ARKG has 4% of its weight in S&P 500 names and XBI has 13%, so ARKG differs more from the index.
Which is cheaper, ARKG or XBI?
ARKG charges 0.75% a year and XBI charges 0.35%, so XBI is cheaper. Fees come from each fund's prospectus.
Other comparisons
ARKG vs IBBARKG vs PBPHARKG vs BBCARKG vs FBTXBI vs IDNAXBI vs GNOMXBI vs GNMXXBI vs BBH
ARKG on its own →XBI on its own →How every figure is computed →Standards and sources →
Where these figures came from
ARKG filings on SEC EDGAR ↗ARKG prospectus with the expense ratio (SEC) ↗ARK page for ARKG ↗XBI filings on SEC EDGAR ↗XBI prospectus with the expense ratio (SEC) ↗State Street website ↗

ETFIQ links to the documents behind every figure; a link is not an endorsement. A comparison is not a recommendation.

How this is computed

It is a position in a set, not a rating, and neither end of it is a recommendation.

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed.

Every figure is an ETFIQ calculation with distributions reinvested.

Cite this page

ETFIQ, ARKG against XBI, data as of Oct 9, 2026. https://etfiq.com/compare/themes/arkg-vs-xbi

Open data

Free to use with attribution for figures ETFIQ computes; issuer data stays under its owner's terms.